HK1037141A1 - Use of endothelin receptor antagonists for producing drugs for controlling obesity. - Google Patents

Use of endothelin receptor antagonists for producing drugs for controlling obesity.

Info

Publication number
HK1037141A1
HK1037141A1 HK01107896A HK01107896A HK1037141A1 HK 1037141 A1 HK1037141 A1 HK 1037141A1 HK 01107896 A HK01107896 A HK 01107896A HK 01107896 A HK01107896 A HK 01107896A HK 1037141 A1 HK1037141 A1 HK 1037141A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
endothelin receptor
controlling obesity
producing drugs
obesity
Prior art date
Application number
HK01107896A
Other languages
English (en)
Inventor
Klaus Munter
Michael Kirchengast
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of HK1037141A1 publication Critical patent/HK1037141A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK01107896A 1997-12-05 2001-11-09 Use of endothelin receptor antagonists for producing drugs for controlling obesity. HK1037141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19754082A DE19754082A1 (de) 1997-12-05 1997-12-05 Methode zur Bekämpfung der Fettleibigkeit
PCT/EP1998/007501 WO1999029308A2 (de) 1997-12-05 1998-11-21 Methode zur bekämpfung der fettleibigkeit

Publications (1)

Publication Number Publication Date
HK1037141A1 true HK1037141A1 (en) 2002-02-01

Family

ID=7850913

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107896A HK1037141A1 (en) 1997-12-05 2001-11-09 Use of endothelin receptor antagonists for producing drugs for controlling obesity.

Country Status (17)

Country Link
US (1) US6197780B1 (ru)
EP (1) EP1035851B1 (ru)
JP (1) JP2002512173A (ru)
KR (1) KR20010032779A (ru)
CN (1) CN1152685C (ru)
AT (1) ATE204172T1 (ru)
AU (1) AU751053B2 (ru)
BR (1) BR9815335A (ru)
CA (1) CA2311423C (ru)
CZ (1) CZ300442B6 (ru)
DE (2) DE19754082A1 (ru)
ES (1) ES2162493T3 (ru)
HK (1) HK1037141A1 (ru)
HU (1) HUP0100171A3 (ru)
NO (2) NO324694B1 (ru)
RU (1) RU2292891C2 (ru)
WO (1) WO1999029308A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP1130027A1 (de) * 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050175667A1 (en) * 2004-02-10 2005-08-11 Wenda Carlyle Use of endothelin antagonists to prevent restenosis
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
PL3628320T3 (pl) 2011-11-11 2022-07-25 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
WO2016099233A2 (ru) * 2014-10-20 2016-06-23 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
SI3380479T1 (sl) 2015-11-25 2023-04-28 Gilead Apollo, Llc Triazolni inhibitorji ACC in uporabe le-teh
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
EP3379933B1 (en) 2015-11-25 2023-02-15 Gilead Apollo, LLC Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
EP4364795A3 (en) 2016-03-02 2024-08-14 Gilead Apollo, LLC Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012499A1 (en) * 1992-12-01 1994-06-09 The Green Cross Corporation 1,8-naphthyridin-2-one derivative and use thereof_
WO1997008169A1 (en) 1995-08-24 1997-03-06 Warner-Lambert Company Furanone endothelin antagonists
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
RU2292891C2 (ru) 2007-02-10
US6197780B1 (en) 2001-03-06
KR20010032779A (ko) 2001-04-25
WO1999029308A3 (de) 1999-09-30
CZ300442B6 (cs) 2009-05-20
WO1999029308A2 (de) 1999-06-17
AU2153599A (en) 1999-06-28
DE19754082A1 (de) 1999-06-10
ATE204172T1 (de) 2001-09-15
EP1035851A2 (de) 2000-09-20
ES2162493T3 (es) 2001-12-16
CA2311423A1 (en) 1999-06-17
BR9815335A (pt) 2000-10-17
CN1152685C (zh) 2004-06-09
DE59801230D1 (de) 2001-09-20
HUP0100171A2 (hu) 2003-02-28
JP2002512173A (ja) 2002-04-23
CN1301162A (zh) 2001-06-27
NO20002777D0 (no) 2000-05-30
HUP0100171A3 (en) 2003-10-28
EP1035851B1 (de) 2001-08-16
AU751053B2 (en) 2002-08-08
NO20002777L (no) 2000-06-02
CA2311423C (en) 2008-01-29
NO20074419L (no) 2000-06-02
NO324694B1 (no) 2007-12-03
RU2003138080A (ru) 2005-06-10
CZ20002006A3 (cs) 2000-11-15

Similar Documents

Publication Publication Date Title
HK1037141A1 (en) Use of endothelin receptor antagonists for producing drugs for controlling obesity.
EP1958965A3 (en) Agonist antibodies to a musk receptor, and their therapeutic uses
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
PT1047781E (pt) Receptores de il-18
EE04630B1 (et) Tsentraalse kannabinoidretseptori antagonistide kasutamine ravimi valmistamisel apetentsi reguleerimiseks
IL129968A (en) Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
AU4597796A (en) Steroid receptor modulator compounds and methods
PL352367A1 (en) Glucagon antagonists/inverse agonists
AU9386398A (en) Cysteine rich receptors: trail
AR019671A1 (es) Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento
ZA969775B (en) Endothelin receptor antagonists.
EP1181555A4 (en) CANCER TREATMENT WITH ENDOTHELINE RECEPTOR ANTAGONISTS
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
EP0759441A3 (en) Methods of treating neuropeptide Y-associated conditions
AU2675795A (en) Tbp2 fragments of the transferrine receptor of neisseria meningitidis
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
NZ337087A (en) C-terminal fragment of pancreatic lipase for hyperlipaemia, obesity, and cardiovascular disorders
EP1090994A3 (en) Peptide repeat immunogens
AU3087599A (en) Human appetite control by glucagon-like peptide receptor binding compounds
EP0754464A3 (en) Methods of treating neuropeptide Y-associated conditions
WO1995022609A3 (en) Human glutamate receptor proteins
ZA966552B (en) Endothelin receptor antagonists.
WO1999053064A3 (en) Methods of delivering glp-1
PT759759E (pt) Promotores para o receptor do tnf p75

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141121